Review synthesizes epidemiological data on hypercortisolism in hypertension, suggesting improved diagnosis may enhance outcomes.
Endogenous hypercortisolism (EHC) is an underrecognised and clinically significant contributor to hypertension, particularly resistant hypertension. Once viewed as a rare entity, EHC is now understood as a spectrum of cortisol excess associated with adverse cardiometabolic outcomes and target-organ damage. Recent large-scale studies demonstrate a much higher prevalence of EHC among patients with resistant hypertension and difficult-to-control diabetes, often in the absence of classic Cushingoid features. This review synthesises recent large-scale epidemiological data pertaining to EHC in hypertension, and discusses the various diagnostic modalities, highlighting the need for systematic screening, which may improve outcomes in resistant hypertension.
No takes yet. Share an insight, caveat, or question.
Dhaybi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: